Arrowhead Pharmaceuticals, Inc. (ARWR)

Several key events have impacted ARWR's stock price in the past six months. The approval and launch of Rudemplo in the U.S., Canada, and China marked Arrowhead's transition to a commercial-stage company. The U.S. FDA granted Breakthrough Therapy Designation to plozasiran for severe hypertriglyceridemia. Arrowhead announced upsized public offerings of $625 million in convertible senior notes and 3.1 million shares of common stock to fund general corporate purposes. Interim clinical data for obesity candidates ARO-INHBE and ARO-ALK7 showed promising reductions in fat and weight. Multiple analysts raised their price targets and maintained "Buy" or "Overweight" ratings. Recent insider selling activity was noted as a potential concern.

Demand seasonality for Arrowhead Pharmaceuticals is likely minimal because the company focuses on developing treatments for chronic and rare genetic diseases. The demand for its therapies is generally consistent throughout the year, driven by ongoing medical needs rather than seasonal fluctuations. The company's revenue is primarily influenced by research and development milestones, successful clinical trial outcomes, regulatory approvals, and strategic partnership agreements, which are event-driven rather than seasonally dependent.

Arrowhead Pharmaceuticals is a biotechnology company that develops innovative medicines for diseases with a genetic origin, primarily using RNA interference (RNAi) to silence disease-causing genes. Its core business revolves around its proprietary Targeted RNAi Molecule (TRiM™) platform, designed for tissue-specific delivery of RNAi therapies. The company's portfolio targets a range of conditions, including cardiovascular, cardiometabolic, central nervous system, pulmonary, liver, muscular, and complement-mediated diseases. Its first commercial product, Rudemplo, received approval in the U.S., Canada, and China in November 2025 for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). Arrowhead has a robust pipeline with approximately 20 clinical assets expected by the end of 2025, with half being partnered programs.

Arrowhead Pharmaceuticals is headquartered in Pasadena, California, and maintains R&D facilities in Madison, Wisconsin, and San Diego, California, as well as a chemistry and manufacturing site in Verona, Wisconsin. Internationally, Arrowhead has an office in Dublin, Ireland, and subsidiaries in Australia and China. Its first commercial product, Rudemplo, is approved in the U.S., Canada, and China. The company's stock is also traded on several international exchanges, including in Germany, the UK, Mexico, and Brazil.

Arrowhead Pharmaceuticals' brand reputation in the past year has been largely positive, driven by commercial success with Rudemplo, promising pipeline data for obesity candidates, strategic partnerships, regulatory endorsement from the FDA, and analyst confidence. However, a patent infringement lawsuit filed by Ionis and financial scrutiny due to net losses, negative EPS, and a high Beneish M-Score presented potential challenges.

Institutional investors hold a significant majority of Arrowhead Pharmaceuticals' shares, ranging from 69% to 84.81%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Avoro Capital Advisors LLC, State Street Corp, and Fmr Llc. Hedge funds control approximately 8.0% of the shares. Individual investors own about 4.4% of the company, with David M. Knott and CEO Christopher Anzalone being among the largest individual shareholders.